LONDON, April 16 (Reuters) - Revenues of the world’s publicly-traded biotech companies topped $70 billion for the first time last year and the sector’s success is being rewarded by record premiums in M&A deals, according to a new report.Ernst & Young, whose annual review is widely followed in the industry, said on Monday soaring prices being paid for assets reflects biotechnology’s now pivotal position in drug discovery.>>> Discuss This Story
